{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:26:11Z","timestamp":1789698371115,"version":"4.0.1"},"reference-count":98,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In recent decades, the use of alpha; pure beta; or beta\/gamma emitters in oncology, endocrinology, and interventional cardiology rheumatology, has proved to be an important alternative to the most common therapeutic regimens. Among radionuclides used for therapy in nuclear medicine, two rhenium radioisotopes are of particular relevance: rhenium-186 and rhenium-188. The first is routinely produced in nuclear reactors by direct neutron activation of rhenium-186 via 185Re(n,\u03b3)186Re nuclear reaction. Rhenium-188 is produced by the decay of the parent tungsten-188. Separation of rhenium-188 is mainly performed using a chromatographic 188W\/188Re generator in which tungsten-188 is adsorbed on the alumina column, similar to the 99Mo\/99mTc generator system, and the radionuclide eluted in saline solution. The application of rhenium-186 and rhenium-188 depends on their specific activity. Rhenium-186 is produced in low specific activity and is mainly used for labeling particles or diphosphonates for bone pain palliation. Whereas, rhenium-188 of high specific activity can be used for labeling peptides or bioactive molecules. One of the advantages of rhenium is its chemical similarity with technetium. So, diagnostic technetium analogs labeled with radiorhenium can be developed for therapeutic applications. Clinical trials promoting the use of 186\/188Re-radiopharmaceuticals is, in particular, are discussed.<\/jats:p>","DOI":"10.3390\/molecules27165283","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T23:28:41Z","timestamp":1660865321000},"page":"5283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Rhenium Radioisotopes for Medicine, a Focus on Production and Applications"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-0718","authenticated-orcid":false,"given":"Licia","family":"Uccelli","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4059-4814","authenticated-orcid":false,"given":"Petra","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-3898","authenticated-orcid":false,"given":"Luca","family":"Urso","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-1899","authenticated-orcid":false,"given":"Teresa","family":"Ghirardi","sequence":"additional","affiliation":[{"name":"Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Marvelli","sequence":"additional","affiliation":[{"name":"Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-804X","authenticated-orcid":false,"given":"Corrado","family":"Cittanti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-6042","authenticated-orcid":false,"given":"Aldo","family":"Carnevale","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Radiology Unit, University Hospital, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchiore","family":"Giganti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"},{"name":"Radiology Unit, University Hospital, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Bartolomei","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-1944","authenticated-orcid":false,"given":"Alessandra","family":"Boschi","sequence":"additional","affiliation":[{"name":"Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1524\/ract.2001.89.4-5.189","article-title":"Nuclear data for medical applications: An overview","volume":"89","author":"Qaim","year":"2001","journal-title":"Radiochim. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Boschi, A., Martini, P., and Uccelli, L. (2017). 188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy. Pharmaceuticals, 10.","DOI":"10.3390\/ph10010012"},{"key":"ref_3","first-page":"4S","article-title":"Radiobiologic Principles in Radionuclide Therapy","volume":"46","author":"Kassis","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Uccelli, L., Boschi, A., Cittanti, C., Martini, P., Panareo, S., Tonini, E., Nieri, A., Urso, L., Caracciolo, M., and Lodi, L. (2021). 90Y\/177Lu-DOTATOC: From preclinical studies to application in humans. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091463"},{"key":"ref_5","unstructured":"NNDC (2022, August 07). National Nuclear Data Center, Available online: https:\/\/www.nndc.bnl.gov\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nucmedbio.2017.02.006","article-title":"Bulk production and evaluation of high specific activity 186gRe for cancer therapy using enriched 186WO3 targets in a proton beam","volume":"49","author":"Mastren","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.nds.2022.06.001","article-title":"Nuclear Data Sheets for A=186","volume":"183","author":"Batchelder","year":"2022","journal-title":"Nucl. Data Sheets"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0969-8043(97)00038-9","article-title":"Reactor-produced radionuclides at the University of Missouri Research Reactor","volume":"49","author":"Ehrhardt","year":"1998","journal-title":"Appl. Radiat. Isot."},{"key":"ref_9","unstructured":"(2022, August 07). NuDat 3, Available online: https:\/\/www.nndc.bnl.gov\/nudat3\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10967-009-0147-y","article-title":"Production possibility of 186 Re via the 192 Os(p,a3n) 186 Re nuclear reaction","volume":"282","author":"Steyn","year":"2009","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1524\/ract.2010.1733","article-title":"Evaluation of charged particle induced reaction cross section data for production of the important therapeutic radionuclide 186Re","volume":"98","author":"Hussain","year":"2010","journal-title":"Radiochim. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.apradiso.2016.06.021","article-title":"Deuteron irradiation of W and WO3 for production of high specific activity 186Re: Challenges associated with thick target preparation","volume":"115","author":"Balkin","year":"2016","journal-title":"Appl. Radiat. Isot."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1515\/ract-2017-2780","article-title":"Scale-up of high specific activity 186gRe production using graphite-encased thick 186W targets and demonstration of an efficient target recycling process","volume":"105","author":"Balkin","year":"2017","journal-title":"Radiochim. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nucmedbio.2005.09.006","article-title":"Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin","volume":"33","author":"Moustapha","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.nucmedbio.2015.03.001","article-title":"Production and separation of 186gRe from proton bombardment of 186WC","volume":"42","author":"Richards","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1524\/ract.2000.88.3-4.163","article-title":"Thermochromatographic separation of no-carrier-added 186Re or 188Re from tungsten targets relevant to nuclear medical applications","volume":"88","author":"Novgorodov","year":"2000","journal-title":"Radiochim. Acta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5923609","DOI":"10.1155\/2017\/5923609","article-title":"Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy","volume":"2017","author":"Uccelli","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Knapp, F.F., Kropp, J., and Liepe, K. (2012). Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy. Therapeutic Nuclear Medicine, Springer. (In Russian).","DOI":"10.1007\/174_2012_669"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"529406","DOI":"10.1155\/2014\/529406","article-title":"188W\/188Re generator system and its therapeutic applications","volume":"2014","author":"Boschi","year":"2014","journal-title":"J. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mirzadeh, S., Knapp, F.F., and Callahan, A.P. (1991, January 13\u201317). Production of Tungsten-188 and Osmium-194 in a Nuclear Reactor for New Clinical Generators. Proceedings of the International Conference, Forschungszentrum J\u00fclich, Germany.","DOI":"10.1007\/978-3-642-58113-7_169"},{"key":"ref_21","first-page":"337","article-title":"Rhenium-188\u2013A Generator-Derived Radioisotope for Cancer Therapy","volume":"13","author":"Knapp","year":"2009","journal-title":"Cancer Biother. Radiopharm"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/00006231-200409000-00014","article-title":"Concentration of 99mtco4\u2212\/reo4\u2212 by a single, compact, anion exchange cartridge","volume":"25","author":"Mushtaq","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.apradiso.2010.06.022","article-title":"Post-elution concentration of 188Re by an electrochemical method","volume":"68","author":"Chakravarty","year":"2010","journal-title":"Appl. Radiat. Isot."},{"key":"ref_24","unstructured":"Khomutov, N.E. (1969). Electrochemistry: Electrodeposition of Metals and Alloys, Achievements in Science: Chemistry Series, Israel Program for Scientific Translations."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0883-2897(86)90027-9","article-title":"The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine","volume":"13","author":"Deutsch","year":"1986","journal-title":"Int. J. Radiat. Appl. Instrum. Part B Nucl. Med. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.nucmedbio.2015.01.007","article-title":"Drug composition matters: The influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP","volume":"42","author":"Lange","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.apradiso.2018.03.018","article-title":"Improved freeze-dried kit for the preparation of 188ReN-DEDC\/lipiodol for the therapy of unresectable hepatocellular carcinoma","volume":"137","author":"Mallia","year":"2018","journal-title":"Appl. Radiat. Isot."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0969-8051(00)00079-2","article-title":"An alternative approach to the preparation of 188Re radiopharmaceuticals from generator-produced [188ReO4]\u2212: Efficient synthesis of 188Re(V)-meso-2,3-dimercaptosuccinic acid","volume":"27","author":"Bolzati","year":"2000","journal-title":"Nucl. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0969-8051(03)00002-7","article-title":"High-yield synthesis of the terminal 188Re\u2261N multiple bond from generator-produced [188ReO4]\u2212","volume":"30","author":"Boschi","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.apradiso.2014.06.003","article-title":"Preparation and first biological evaluation of novel Re-188\/Tc-99m peptide conjugates with substance-P","volume":"92","author":"Smilkov","year":"2014","journal-title":"Appl. Radiat. Isot."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/18744710113069990022","article-title":"Mixed Tridentate \u03c0-Donor and Monodentate \u03c0-Acceptor Ligands as Chelating Systems for Rhenium-188 and Technetium-99m Nitrido Radiopharmaceuticals","volume":"6","author":"Boschi","year":"2014","journal-title":"Curr. Radiopharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0010-8545(98)00095-2","article-title":"Rhenium 1996","volume":"172","author":"Vites","year":"1998","journal-title":"Coord. Chem. Rev."},{"key":"ref_33","first-page":"1992","article-title":"186Re-Liposome Labeling Using 186Re-SNS\/S Complexes: In Vitro Stability, Imaging, and Biodistribution in Rats","volume":"44","author":"Bao","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2012\/278306","article-title":"Re-SSS\/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside","volume":"2012","author":"Lepareur","year":"2012","journal-title":"Int. J. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"N50","DOI":"10.3413\/nuk2015050001","article-title":"Discovery of rhenium and masurium (technetium) by Ida Noddack-Tacke and Walter Noddack","volume":"54","author":"Biersack","year":"2015","journal-title":"Nuklearmedizin\/Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2019.04.014","article-title":"Organometallic and coordination rhenium compounds and their potential in cancer therapy","volume":"393","author":"Bauer","year":"2019","journal-title":"Coord. Chem. Rev."},{"key":"ref_38","first-page":"797","article-title":"Rhenium-188 as a Possible Diagnostic Agent","volume":"7","author":"Hajes","year":"1966","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0014-4886(76)90230-2","article-title":"Transport and distribution of rhenium-188 in the central nervous system","volume":"50","author":"Bardfeld","year":"1976","journal-title":"Exp. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Spencer, R.P. (1977). Therapy in Nuclear Medicine, Grune & Stratton Publisher.","DOI":"10.1016\/0047-0740(77)90149-8"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Uccelli, L., Martini, P., Cittanti, C., Carnevale, A., Missiroli, L., Giganti, M., Bartolomei, M., and Boschi, A. (2019). Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008\u20132018). Molecules, 24.","DOI":"10.3390\/molecules24030640"},{"key":"ref_42","unstructured":"(2022, July 21). Search of: Rhenium\u2014List Results\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Rhenium&cntry=&state=&city=&dist=."},{"key":"ref_43","unstructured":"(2022, August 07). Home\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/neuonc\/nos060","article-title":"Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma","volume":"14","author":"Phillips","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chang, C.-H., Chang, M.-C., Chang, Y.-J., Chen, L.-C., Lee, T.-W., and Ting, G. (2021). Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083868"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ii186","DOI":"10.1093\/neuonc\/noaa215.777","article-title":"RADT-24. High Absorbed Doses of Rhenium-186 Nanoliposomes (Rnl) in Recurrent Gbm: A Phase 1 Study","volume":"22","author":"Brenner","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"045012","DOI":"10.1088\/2057-1976\/ac02a6","article-title":"Patient specific, imaging-informed modeling of rhenium-186 nanoliposome delivery via convection-enhanced delivery in glioblastoma multiforme","volume":"7","author":"Woodall","year":"2021","journal-title":"Biomed. Phys. Eng. Express"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/09546634.2020.1793890","article-title":"Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: A long-term retrospective study","volume":"33","author":"Cipriani","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00259-020-05088-z","article-title":"High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): Single center preliminary results","volume":"48","author":"Castellucci","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1758834016640494","article-title":"From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases","volume":"8","author":"Liepe","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1016\/j.clgc.2018.11.014","article-title":"Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone","volume":"17","author":"Bloemendal","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2967\/jnumed.111.093674","article-title":"Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis","volume":"52","author":"Biersack","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/jm061290i","article-title":"Somatostatin Receptor-Binding Peptides Suitable for Tumor Radiotherapy with Re-188 or Re-186. Chemistry and Initial Biological Studies","volume":"50","author":"Cyr","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/jm950111m","article-title":"Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m:\u2009 Chemistry and Initial Biological Studies","volume":"39","author":"Pearson","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/JTO.0b013e3181bf1070","article-title":"Targeted Radiopharmaceutical Therapy for Advanced Lung Cancer: Phase I Trial of Rhenium Re188 P2045, a Somatostatin Analog","volume":"4","author":"Edelman","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_56","unstructured":"(2022, July 21). Phase I\/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02030184."},{"key":"ref_57","unstructured":"(2022, July 21). Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00100256."},{"key":"ref_58","first-page":"79","article-title":"Transarterial Radionuclide Therapy with 188 Re-Labelled Lipiodol","volume":"56","author":"Lepareur","year":"2017","journal-title":"Int. J. Nucl. Med. Res. Spec. Issue"},{"key":"ref_59","first-page":"2033","article-title":"Lipiodol Solution of 188 Re-HDD as a New Therapeutic Agent for Transhepatic Arterial Embolization in Liver Cancer: Preclinical Study in a Rabbit Liver Cancer Model","volume":"44","author":"Paeng","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/01.mnm.0000130241.22068.45","article-title":"A kit formulation for the preparation of re-lipiodol: Preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma","volume":"25","author":"Boschi","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_61","first-page":"382","article-title":"Preliminary Experience in Radionuclide Therapy of Hepatocellular Carcinoma Using Hepatic Intra-arterial Radio-conjugates","volume":"31","author":"Keng","year":"2002","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00259-003-1363-2","article-title":"Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma","volume":"31","author":"Sundram","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1148\/radiol.2432051246","article-title":"Inoperable hepatocellular carcinoma: Transarterial 188Re HDD-labeled iodized oil for treatment\u2013Prospective multicenter clinical trial","volume":"243","author":"Kumar","year":"2007","journal-title":"Radiology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ijrobp.2007.05.009","article-title":"Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-Sponsored Multination Study","volume":"69","author":"Bernal","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/j.semnuclmed.2007.10.006","article-title":"International Atomic Energy Agency-Sponsored Multination Study of Intra-Arterial Rhenium-188-Labeled Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results With Special Emphasis on Prognostic Value of Dosimetric Study","volume":"38","author":"Bernal","year":"2008","journal-title":"Semin. Nucl. Med."},{"key":"ref_66","first-page":"612","article-title":"Biologic Dosimetry of 188 Re-HDD\/Lipiodol Versus 131 I-Lipiodol Therapy in Patients with Hepatocellular Carcinoma","volume":"45","author":"Lambert","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_67","first-page":"60","article-title":"188 Re-HDD\/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial","volume":"46","author":"Lambert","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_68","first-page":"1326","article-title":"188 Re-HDD\/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis","volume":"46","author":"Lambert","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_69","first-page":"209","article-title":"Radiolabeled Lipiodol Therapy for Hepatocellular Carcinoma in Patients Awaiting Liver Transplantation: Pathology of the Explant Livers and Clinical Outcome","volume":"20","author":"Lambert","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejrex.2005.07.016","article-title":"Transarterial radionuclide therapy with Re-188-HDD-lipiodol in case of unresectable hepatocellular carcinoma with extensive portal vein thrombosis","volume":"56","author":"Kumar","year":"2005","journal-title":"Eur. J. Radiol. Extra"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.RVI.0000195321.20579.F2","article-title":"Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil","volume":"17","author":"Kumar","year":"2006","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00042737-200602000-00016","article-title":"Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol","volume":"18","author":"Kumar","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00259-005-1954-1","article-title":"188Re-HDD\/lipiodol therapy for hepatocellular carcinoma: An activity escalation study","volume":"33","author":"Lambert","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.semnuclmed.2007.10.002","article-title":"A Report on the Implementation Aspects of the International Atomic Energy Agency\u2019s First Doctoral Coordinated Research Project, \u2018Management of Liver Cancer Using Radionuclide Methods With Special Emphasis on Trans-Arterial Radio-Conjugate Therapy and Internal Dosimetry\u2019","volume":"38","author":"Padhy","year":"2008","journal-title":"Semin. Nucl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000343876","article-title":"Yttrium-90 Microspheres: A review of its emerging clinical indications","volume":"4","author":"Khajornjiraphan","year":"2015","journal-title":"Liver Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2016.01.008","article-title":"Intra-arterial radionuclide therapies for liver tumors","volume":"46","author":"Bozkurt","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1435302","DOI":"10.1155\/2018\/1435302","article-title":"Transarterial radioembolization (TARE) agents beyond 90 Y-microspheres","volume":"2018","author":"Bouvry","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40658-018-0227-6","article-title":"Biodistribution, pharmacokinetics, and organ-level dosimetry for 188 Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT\/CT scans","volume":"5","author":"Esquinas","year":"2018","journal-title":"EJNMMI Phys."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.nucmedbio.2014.11.013","article-title":"Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD\/lipiodol","volume":"42","author":"Banka","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s00259-019-04277-9","article-title":"Preliminary results of the Phase 1 Lip-Re I clinical trial: Biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization","volume":"46","author":"Delaunay","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_81","unstructured":"(2022, July 21). 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01126463?term=rhenium."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.apradiso.2010.11.001","article-title":"Automation of labelling of Lipiodol with high-activity generator-produced 188Re","volume":"69","author":"Lepareur","year":"2011","journal-title":"Appl. Radiat. Isot."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nucmedbio.2010.08.011","article-title":"Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma","volume":"38","author":"Uccelli","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2967\/jnumed.118.224170","article-title":"Early Phase I Study of a 99mTc-Labeled Anti\u2013Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT\/CT Assessment of PD-L1 Expression in Non\u2013Small Cell Lung Cancer","volume":"60","author":"Xing","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: Outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7150\/thno.8006","article-title":"Nanobody: The \u201cMagic Bullet\u201d for Molecular Imaging?","volume":"4","author":"Chakravarty","year":"2014","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1096\/fj.10-180331","article-title":"Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer","volume":"25","author":"Vaneycken","year":"2011","journal-title":"FASEB J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11307-017-1082-x","article-title":"Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation","volume":"19","author":"Zhou","year":"2017","journal-title":"Mol. Imaging Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1021\/acs.molpharmaceut.9b00354","article-title":"Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior","volume":"16","author":"Dekempeneer","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acs.molpharmaceut.7b00985","article-title":"Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted \u03b1-Particle Therapy of Cancer","volume":"15","author":"Pruszynski","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Bridoux, J., Broos, K., Lecocq, Q., Debie, P., Martin, C., Ballet, S., Raes, G., Neyt, S., Vanhove, C., and Breckpot, K. (2020). Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules, 10.","DOI":"10.3390\/biom10101388"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2967\/jnumed.112.111021","article-title":"Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer","volume":"54","author":"Xavier","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I Study of 68Ga-HER2-Nanobody for PET\/CT Assessment of HER2 Expression in Breast Carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s11307-018-01302-5","article-title":"Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET\/CT Imaging of Protumorigenic Macrophages","volume":"21","author":"Xavier","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1021\/acs.molpharmaceut.1c00569","article-title":"Development of a 99mTc-Labeled Single-Domain Antibody for SPECT\/CT Assessment of HER2 Expression in Breast Cancer","volume":"18","author":"Zhao","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e15569","DOI":"10.1200\/JCO.2018.36.15_suppl.e15569","article-title":"In situ anti-cancer agent derived from [188re]rhenium nitro-imidazole ligand loaded poly-l-lysine dendrimer administrated by direct CT guided stereotactic intrahepatic injection","volume":"36","author":"Chen","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JGO.2019.5.suppl.96","article-title":"Novel CT-guided 188-rhenium brachytherapy device for local primary and secondary lung malignancies","volume":"5","author":"Chen","year":"2019","journal-title":"J. Glob. Oncol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/16\/5283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:11:57Z","timestamp":1760141517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/16\/5283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":98,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["molecules27165283"],"URL":"https:\/\/doi.org\/10.3390\/molecules27165283","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}